Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 9/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24955626 | 1.00 | PIK3CA (0.42) | PIK3CAMTORKDM4EKMT2APDE9A | |
| SCHEMBL31106958 | 0.84 | PDE2A (0.46) | PIK3CAMTORKMT2APDE2A | |
| SCHEMBL24955621 | 0.84 | PDE2A (0.46) | PIK3CAMTORKMT2APDE2A | |
| SCHEMBL31106993 | 0.82 | PIK3CA (0.40) | PIK3CAMTORKDM4EKMT2APDE9A | |
| SCHEMBL24955664 | 0.82 | PIK3CA (0.40) | PIK3CAMTORKDM4EKMT2APDE9A | |
| SCHEMBL16058862 | 0.81 | SMN1; SMN2 (0.47) | PIK3CAMTORKMT2APDE9ASMN1; SMN2 | |
| SCHEMBL24954192 | 0.81 | PIK3CA (0.39) | PIK3CAMTORKDM4EKMT2APDE9A | |
| SCHEMBL24955619 | 0.81 | PIK3CA (0.42) | PIK3CAMTOR | |
| SCHEMBL31106974 | 0.81 | PIK3CA (0.42) | PIK3CAMTOR | |
| SCHEMBL24955763 | 0.80 | CNR2 (0.38) | PIK3CAMTORCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | PIK3CA 2011/4885MTOR 777/4885KDM4E 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.